These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19585719)

  • 1. Alemtuzumab: new indication. First line treatment of chronic lymphocytic leukaemia: continue to use oral chlorambucil.
    Prescrire Int; 2009 Apr; 18(100):60. PubMed ID: 19585719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fludarabine: new indication. First-line treatment of CLL: unconvincing evidence.
    Prescrire Int; 2005 Feb; 14(75):3-5. PubMed ID: 15747447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
    Demko S; Summers J; Keegan P; Pazdur R
    Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.
    Hillmen P; Skotnicki AB; Robak T; Jaksic B; Dmoszynska A; Wu J; Sirard C; Mayer J
    J Clin Oncol; 2007 Dec; 25(35):5616-23. PubMed ID: 17984186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Hadj Tahar A
    Issues Emerg Health Technol; 2005 Mar; (66):1-4. PubMed ID: 15806747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Robak T
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic lymphocytic leukaemia: only treat when symptomatic.
    Prescrire Int; 2002 Oct; 11(61):156-7. PubMed ID: 12378749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab. Chronic lymphoid leukaemia: no decisive advantage.
    Prescrire Int; 2010 Apr; 19(106):56-8. PubMed ID: 20568482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibody licensed for third-line treatment of B-cell chronic lymphocytic leukemia.
    Thompson CA
    Am J Health Syst Pharm; 2001 Jul; 58(13):1174. PubMed ID: 11449871
    [No Abstract]   [Full Text] [Related]  

  • 10. Hillmen trial of alemtuzumab in first-line chronic lymphocytic leukemia still provides valuable information.
    Sirard C; Trehu EG
    J Clin Oncol; 2008 May; 26(14):2411-2; author reply 2412-3. PubMed ID: 18467736
    [No Abstract]   [Full Text] [Related]  

  • 11. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
    Laros-van Gorkom BA; Huisman CA; Wijermans PW; Schipperus MR
    Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab.
    Williamson TS
    Clin J Oncol Nurs; 2001; 5(6):287-8. PubMed ID: 11899633
    [No Abstract]   [Full Text] [Related]  

  • 13. Taking the measure of alemtuzumab.
    Gilleece MH
    Leuk Res; 2004 Dec; 28(12):1253-4. PubMed ID: 15475064
    [No Abstract]   [Full Text] [Related]  

  • 14. [Current concepts in chronic lymphocytic leukemia. Better chances for young patients].
    Hallek M; Bergmann M; Goede V; Fingerle-Rowson G; Schweighofer C; Schmitt B; Wendtner CM; Emmerich B
    MMW Fortschr Med; 2003 Jul; 145(27-28):46-9. PubMed ID: 14587189
    [No Abstract]   [Full Text] [Related]  

  • 15. Alemtuzumab.
    Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
    [No Abstract]   [Full Text] [Related]  

  • 16. The evolving role of alemtuzumab in management of patients with CLL.
    Faderl S; Coutré S; Byrd JC; Dearden C; Denes A; Dyer MJ; Gregory SA; Gribben JG; Hillmen P; Keating M; Rosen S; Venugopal P; Rai K
    Leukemia; 2005 Dec; 19(12):2147-52. PubMed ID: 16239912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
    Abad S; Gyan E; Moachon L; Bouscary D; Sicard D; Dreyfus F; Blanche P
    Clin Infect Dis; 2003 Jul; 37(2):e27-8. PubMed ID: 12856232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [First-line therapy of chronic lymphocytic leukemia in the elderly: be careful with overtreatment].
    Bauduer F
    Presse Med; 2009 Jan; 38(1):140-2. PubMed ID: 19004611
    [No Abstract]   [Full Text] [Related]  

  • 19. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects.
    Pettitt AR; Matutes E; Oscier D
    Leukemia; 2006 Aug; 20(8):1441-5. PubMed ID: 16738694
    [No Abstract]   [Full Text] [Related]  

  • 20. Monoclonal antibodies in chronic lymphocytic leukemia.
    Ferrajoli A; Faderl S; Keating MJ
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1231-8. PubMed ID: 17020457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.